Article Information
History
- November 30, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Nidhi S. Mundada, BSc1,
- Julio C. Rojas, MD, PhD1,
- Lawren Vandevrede, MD, PhD1,
- Elisabeth H. Thijssen, PhD1,2,
- Leonardo Iaccarino, PhD1,3,
- Obiora C. Okoye, MD, MPH4,
- Ranjani Shankar, BSc1,
- David N. Soleimani-Meigooni, MD1,
- Argentina L. Lago, PhD1,
- Bruce L. Miller, MD1,
- Charlotte E. Teunissen, PhD2,
- Hillary Heuer, PhD1,
- Howie J. Rosen, MD1,
- Jeffrey L. Dage, PhD5,
- William J. Jagust, MD6,
- Gil D. Rabinovici, MD1,
- Adam L. Boxer, MD, PhD1 and
- Renaud La Joie, PhD1,*
- 1Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
- 2Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
- 3Eli Lilly and Company, Indianapolis, IN, USA
- 4Global Brain Health Institute, San Francisco, CA, USA
- 5Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA
- 6University of California, Berkeley, Berkeley, CA, USA
- ↵* Corresponding author; email: renaud.lajoie{at}ucsf.edu
Posted November 30, 2022.
Head-to-head comparison between plasma p-tau217 and Flortaucipir-PET in amyloid-positive patients with cognitive impairment
